Thanks George , good point on the equity, could be adjusted to suit
Hey Meph personally in my deal the PRV would be hands of, they would be taking the rights to the drug for DMD only in whichever of the 50% global route they took
The PRV would be reserved as the teaser for another partnering deal with one of our new indications, doesn't necessarily have to be an outright cash sale although the value would indirectly added into any partnering talks for a new indication to make the deal look more attractive
See how we go
Chart, page-4257
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.004(5.88%) |
Mkt cap ! $64.91M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.2¢ | 6.9¢ | $91.71K | 1.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 18695 | 1 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
0.004 ( 3.20 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.2¢ | 6.9¢ | 129842 | ||
| Last updated 15.32pm 29/04/2024 ? | |||||
| PER (ASX) Chart |